Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-24T15:54:57.649Z Has data issue: false hasContentIssue false

Chapter 25 - Human Immunodeficiency Virus in Pregnancy (Content last reviewed: 23rd July 2019)

Published online by Cambridge University Press:  15 November 2017

By
Brenna L. Hughes ,
D. Heather Watts ,
Jennifer R. McKinney  and
Catherine S. Eppes
Edited by
David James ,
Philip Steer ,
Carl Weiner ,
Bernard Gonik  and
Stephen Robson
David James
Affiliation:
University of Nottingham
Philip Steer
Affiliation:
Imperial College London
Carl Weiner
Affiliation:
University of Kansas
Bernard Gonik
Affiliation:
Wayne State University, Detroit
Stephen Robson
Affiliation:
University of Newcastle
Get access

Summary

The management of human immunodeficiency virus (HIV) infection continues to evolve rapidly. Amazing advances have been made in therapy of primary infection, prevention of opportunistic infections, and prevention of perinatal transmission since the first cases of acquired immune deficiency syndrome (AIDS) were described in 1981. Perinatal transmission rates have decreased from 20–30% early in the epidemic to < 1% in high-income countries with the use of antiretroviral therapy and scheduled cesarean delivery.

Type
Chapter
Information
High-Risk Pregnancy
Management Options
 , pp. 621 - 643
Publisher: Cambridge University Press
First published in: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Centers for Disease Control and Prevention (CDC). HIV among pregnant women, infants, and children. Updated 2016. http://www.cdc.gov/hiv/group/gender/pregnantwomen (accessed March 2017).Google Scholar
World Health Organization (WHO). Number of women living with HIV. http://www.who.int/gho/hiv/epidemic_status/cases_adults_women_children/en/ (accessed March 2017).Google Scholar
Whitmore, SK, Zhang, X, Taylor, AW, Blair, JM. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr 2011; 57: 218–22. doi: 10.1097/QAI.0b013e3182167dec.Google Scholar
Nesheim, SR, Wiener, J, Fitz Harris, LF, Lampe, MA, Weidle, PJ. Brief report: estimated incidence of perinatally acquired HIV infection in the United States, 1978–2013. J Acquir Immune Defic Syndr 2017; 76: 461–4. doi: 10.1097/QAI.0000000000001552.Google Scholar
UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013, pp. 38–9. http://www.unaids.org/en/resources/documents/2013/20130923_UNAIDS_Global_Report_2013 (accessed March 2017).Google Scholar
DeCock, KM, Fowler, MG, Mercier, E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283: 1175–82.Google Scholar
Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. MMWR Morb Mortal Wkly Rep 2006; 55 (RR-14): 1–17.Google Scholar
Centers for Disease Control and Prevention (CDC). Laboratory testing for the diagnosis of HIV infection: updated recommendations. http://stacks.cdc.gov/view/cdc/23447 (accessed March 2017).Google Scholar
Centers for Disease Control and Prevention (CDC). Success in implementing Public Health Service guidelines to reduce perinatal transmission of HIV-Louisiana, Michigan, New Jersey, and South Carolina, 1993, 1995, and 1996. MMWR Morb Mortal Wkly Rep 1998; 47: 688–91.Google Scholar
Nielsen-Saines, K, Watts, DH, Veloso, VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366: 2368–79.Google Scholar
Wade, NA, Birkhead, GS, Warren, BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409–14.CrossRefGoogle ScholarPubMed
Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): A randomised double-blind placebo-controlled trial. Lancet 2002; 359: 1178–86.Google Scholar
Moodley, D, Moodley, J, Coovadia, H, et al.; South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725–35.Google Scholar
American College of Obstetrics and Gynecology. ACOG Committee Opinion No. 418: Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2008; 112: 739–42.Google Scholar
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf (accessed March 2017).Google Scholar
Saada, M, Le Chenadec, J, Berrebi, A, et al. Pregnancy and progression to AIDS: Results of the French prospective cohorts. AIDS 2000; 14: 2355–60.CrossRefGoogle ScholarPubMed
Burns, DN, Landesman, S, Minkoff, H, et al. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol 1998; 178: 355–9.Google Scholar
Weisser, M, Rudin, C, Battegay, M, et al. Does pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort studies. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 15: 404–10.Google Scholar
Minkoff, H, Hershow, R, Watts, DH, et al. The relationship of pregnancy to HIV disease progression. Am J Obstet Gynecol 2003; 189: 552–9.Google Scholar
Deschamps, MM, Pape, JW, Desvarieux, M, et al. A prospective study of HIV-seropositive asymptomatic women of childbearing age in a developing country. J Acquir Immune Defic Syndr 1993; 6: 446–51.Google Scholar
Kumar, RM, Uduman, SA, Khurrana, AK. Impact of pregnancy on maternal AIDS. J Reprod Med 1993; 42: 429–34.Google Scholar
Calvert, C, Ronsmans, C. Pregnancy and HIV disease progression: a systematic review and meta-analysis. Trop Med Int Health 2015; 20: 122–45.CrossRefGoogle ScholarPubMed
Bristol-Myers Squibb. Dear healthcare provider letter, January 5, 2001. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173947.htm (accessed March 2017).Google Scholar
Hill, JB, Sheffield, JS, Zeeman, GG, Wendel, GD. Hepatotoxicity with antiretroviral treatment of pregnant women. Obstet Gynecol 2001; 98: 909–11.Google Scholar
Ibdah, JA, Yang, Z, Bennett, MJ. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab 2000; 71: 182–9.Google Scholar
Grimbert, S, Fromenty, B, Fisch, C, et al. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. Hepatology 1993; 17: 628–37.CrossRefGoogle ScholarPubMed
Grimbert, S, Fisch, C, Deschamps, D, et al. Effects of female sex hormones on mitochondria: possible role in acute fatty liver of pregnancy. Am J Physiol 1995; 268: G107–15.Google Scholar
Brinkman, K, ter Hofstede, HJM, Burger, DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735–44.Google Scholar
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed March 2017).Google Scholar
Bardeguez, AD, Shapiro, DE, Mofenson, LM, et al. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 2003; 32: 170–81.Google Scholar
Watts, DH, Lambert, J, Stiehm, ER, et al.; PACTG 185 Study Team. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 2003; 33: 585–93.Google Scholar
Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283–96.Google Scholar
Brocklehurst, P, French, R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998; 105: 836–48.Google Scholar
Bucceri, A, Luchini, L, Rancilio, L, et al. Pregnancy outcome among HIV positive and negative intravenous drug users. Eur J Obstet Gynecol Reprod Biol 1997; 72: 169–74.Google Scholar
Ellis, J, Williams, H, Graves, W, Lendsay, MK. Human immunodeficiency virus infection is a risk factor for adverse perinatal outcome. Am J Obstet Gynecol 2002; 186: 903–6.Google Scholar
Leroy, V, Ladner, J, Nyiraziraje, M, et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992–1994. AIDS 1998; 12: 643–50.Google Scholar
Stratton, P, Tuomala, RE, Abboud, R, et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 1999; 20: 179–86.Google Scholar
Lambert, JS, Watts, DH, Mofenson, L, et al.; Pediatric AIDS Clinical Trials Group 185 Team. Risk factors for preterm birth and low birth weight in infants born to HIV-infected pregnant women receiving zidovudine. AIDS 2000; 14: 1389–99.Google Scholar
Sansone, M, Sarno, L, Saccone, G, et al. Risk of preeclampsia in human immunodeficiency virus-infected pregnant women. Obstet Gynecol 2016; 127: 1027–32. doi: 10.1097/AOG.0000000000001424.Google Scholar
Browne, JL, Schrier, VJ, Grobbee, DE, Peters, SA, Klipstein-Grobusch, K. HIV, antiretroviral therapy, and hypertensive disorders in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2015; 70: 91–8. doi: 10.1097/QAI.0000000000000686.Google Scholar
Sebitloane, HM, Moodley, J. Maternal and obstetric complications among HIV-infected women treated with highly active antiretroviral treatment at a regional hospital in Durban, South Africa. Niger J Clin Pract 2017; 20: 1360–7. doi: 10.4103/njcp.njcp_328_16.Google Scholar
Machado, ES, Krauss, MR, Megazzini, K, et al. Hypertension, preeclampsia and eclampsia among HIV-infected pregnant women from Latin America and Caribbean countries. J Infect 2014; 68: 572–80. doi: 10.1016/j.jinf.2013.12.018.Google Scholar
Suy, A, Martinez, E, Coll, O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20: 59–66. PMID: 16327320.CrossRefGoogle ScholarPubMed
Sebitloane, HM, Moodley, J, Sartorius, B. Associations between HIV, highly active anti-retroviral therapy, and hypertensive disorders of pregnancy among maternal deaths in South Africa 2011–2013. Int J Gynaecol Obstet 2017; 136: 195–9. doi: 10.1002/ijgo.12038.CrossRefGoogle ScholarPubMed
Connor, EM, Sperling, RS, Gelber, R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173–80.Google Scholar
European Collaborative Study. Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birth weight? AIDS 1999; 13: 119–24.Google Scholar
Lorenzi, P, Spicher, VM, Laubereau, B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12: F241–7.Google Scholar
European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913–20.Google Scholar
Tuomala, RE, Shapiro, DE, Mofenson, LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 1863–70.CrossRefGoogle ScholarPubMed
Kourtis, AP, Schmid, CH, Jamieson, DJ, Lau, J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21: 607–15.Google Scholar
Townsend, CL, Cortina-Borja, M, Peckham, CS, Tookey, PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019–26.Google Scholar
Machado, ES, Hofer, CB, Costa, TT, et al. Pregnancy outcome in HIV-1 infected women receiving combination antiretroviral therapy prior versus after conception. Sex Transm Inf 2009; 85: 82–7.Google Scholar
Schulte, J, Dominguez, K, Sukalac, T, et al.; Pediatric Spetrum of HIV Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989–2004. Pediatrics 2007; 119: e900–6.Google Scholar
Ravizza, M, Martinelli, P, Bucceri, A, et al.; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Treatment with protease inhibitors and coninfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195: 913–34.Google Scholar
Grosch-Woerner, I, Puch, K, Maier, RF, et al.; Multicenter Interdisciplinary Study Group Germany/Austria. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9: 6–13.Google Scholar
Watts, DH, Williams, PL, Kacanek, D, et al.; Pediatric HIV/AIDS Cohort Study. Combination antiretroviral use and preterm birth. J Infect Dis 2013; 207: 612–21.CrossRefGoogle ScholarPubMed
Cooper, ER, Charurat, M, Mofenson, L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484–94.Google Scholar
Minkoff, H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 2003; 101: 797–810.Google Scholar
Dunn, DT, Newell, ML, Ades, AE, et al. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340: 585–8.Google Scholar
Mofenson, LM, Lambert, JS, Stiehm, ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999; 341: 385–93.Google Scholar
Garcia, PM, Kalish, LA, Pitt, J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341: 394–402.Google Scholar
Stiehm, ER, Lambert, JS, Mofenson, L, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999; 179: 567–75.Google Scholar
Shaffer, N, Chuachoowong, R, Mock, PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353: 773–80.Google Scholar
Lallemant, M, Jourdain, G, Le Coeur, S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000; 343: 982–91.Google Scholar
Wiktor, SZ, Ekpini, E, Karon, J, et al. Short-course zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomised trial. Lancet 1999; 353: 781–5.CrossRefGoogle ScholarPubMed
Dabis, F, Msellati, P, Meda, N, et al. 6-Month efficacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353: 786–92.CrossRefGoogle Scholar
DITRAME ANRS 049 Study Group. 15-Month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. Lancet 1999; 354: 2050.Google Scholar
Dabis, F, Elenga, N, Meda, N, et al.; DITRAME Study Group. 18-Month mortality and perinatal exposure to zidovudine in West Africa. AIDS 2001; 15: 771–9.Google Scholar
Guay, LA, Musoke, P, Fleming, T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother–child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999; 354: 795–802.Google Scholar
Briand, N, Warszawski, J, Mandelbrot, L, et al. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era? Clin Infect Dis 2013; 57: 903–14.Google Scholar
Cotter, AM, Brookfield, KF, Duthely, LM, et al. Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy. Am J Obstet Gynecol 2012; 207: 482.e1–5.Google Scholar
Chiappini, E, Galli, L, Giaquinto, C, et al. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS 2013; 27: 991–1000.CrossRefGoogle ScholarPubMed
Wong, VV. Is peripartum zidovudine absolutely necessary for patients with a viral load less than 1,000 copies/ml? J Obstet Gynaecol 2011; 31: 740–2.Google Scholar
Dorenbaum, A, Cunningham, CK, Gelber, RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288: 189–98.Google Scholar
Townsend, CL, Cortina-Borja, M, Peckham, CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22: 973–81.Google Scholar
Forbes, JC, Alimenti, AM, Singer, J, et al.; Canadian Pediatric AIDS Research Group (CPARG). A national review of vertical HIV transmission. AIDS 2012; 26: 757–63.Google Scholar
daCosta, TP, Machado, ES, et al. Malformations among HIV vertically exposed newborns: results from a Brazilian cohort study. Paper presented at the 6th IAS Conference on HIV Pathogenesis and Treatment and Prevention, 2011, Rome, Italy.Google Scholar
Watts, DH, Huang, S, Culnane, M, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med 2011; 39: 163–70.Google Scholar
Knapp, KM, Brogly, SB, Muenz, DG, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012; 31: 164–70.Google Scholar
Floridia, M, Mastroiacovo, P, Tamburrini, E, et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001–2011. BJOG 2013; 120: 1466–75.Google Scholar
Sibiude, J, Mandelbrot, L, Blanche, S, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med 2014; 11: e1001635.Google Scholar
Williams, PL, Crain, MJ, Yildirim, C, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr 2015; 169: 48–55.Google Scholar
Antiretroviral Pregnancy Registry. Interim Report, 1 January 1989 Through 31 July 2016. http://www.apregistry.com/forms/interim_report.pdf (accessed March 2017).Google Scholar
Ford, N, Mofenson, L, Shubber, Z, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2014; 28 (Suppl 2): S123–31.Google Scholar
Watts, DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep 2007; 4: 135–40.Google Scholar
Watts, DH, Li, D, Handelsman, E, et al. Assessment of birth defects according to maternal therapy among infants in WITS. J Acquir Immune Defic Syndr 2007; 44 : 299–305.Google Scholar
Brogly, SB, Abzug, MJ, Watts, DH, et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 2010; 29: 721–7.Google Scholar
Hleyhel, M, Goujon, S, Delteil, C, et al. Risk of cancer in children exposed to didanosine in utero. AIDS 2016; 30: 1245–56. doi: 10.1097/QAD.0000000000001051.Google Scholar
Caniglia, EC, Patel, K, Huo, Y, et al. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study. AIDS 2016; 30: 1267–78. doi: 10.1097/QAD.0000000000001052.Google Scholar
Rough, K, Sun, JW, Seage, GR, et al. Zidovudine use in pregnancy and congenital malformations. AIDS 2017; 31: 1733–43. doi: 10.1097/QAD.0000000000001549.CrossRefGoogle ScholarPubMed
Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 January 1989–31 January 2018. Wilmington, NC: Registry Coordinating Center, 2018. www.apregistry.com (accessed August 2019).Google Scholar
Drug Safety, FDA Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq). www.fda.gov/Drugs/DrugSafety/ucm608112.htm (accessed September 2018).Google Scholar
Blanche, S, Tardieu, M, Rustin, P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084–9.Google Scholar
Mandelbrot, L, Landreau-Mascaro, A, Rekacewicz, C, et al. Lamivudine–zidovudine combination for prevention of maternal–infant transmission of HIV-1. JAMA 2001; 285: 2129–31.CrossRefGoogle ScholarPubMed
Foster, C, Lyall, H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 2008;61 : 8–12.CrossRefGoogle ScholarPubMed
Brogly, SB, Ylitalo, N, Mofenson, LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21: 929–38.Google Scholar
Benhammou, V, Tardieu, M, Warszawski, J, Rustin, P, Blanche, S. Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environ Mol Mutagen 2007; 48: 173–8.Google Scholar
Olivero, OA, Anderson, LM, Diwan, BA, et al. Transplacental effects of 3’-azido-2’3’-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89: 1602–8.CrossRefGoogle ScholarPubMed
Ayers, KM, Torrey, CE, Reynolds, DJ. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundament Appl Toxicol 1997; 38: 195–8.Google Scholar
Hanson, IC, Antonelli, TA, Sperling, RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 463–7.Google Scholar
Brogly, S, Williams, P, Seage, GR, Van Dyke, R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the Pediatric AIDS Clinical Trials Group 219 and 219C cohorts. J Acquir Immune Defic Syndr 2006; 41: 535–6.Google Scholar
Pollock, BH, Jenson, HB, Leach, CT, et al. Risk factors for pediatric human immunodeficiency virus related malignancy. JAMA 2003; 289: 2393–9.Google Scholar
Hankin, C, Lyall, H, Peckham, C, Tookey, PA. Monitoring death and cancer in children born to HIV-infected women in England and Wales: use of HIV surveillance and national routine data. AIDS 2007; 21: 867–77.Google Scholar
Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (accessed March 2017).Google Scholar
Hirsch, MS, Gunthard, HF, Schapiro, JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society–USA Panel. Clin Infect Dis 2008; 47: 266–85.Google Scholar
Nolan, M, Fowler, MG, Mofenson, LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr 2002; 30: 216–29.Google Scholar
International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977–87.Google Scholar
European Mode of Delivery Collaboration. Elective cesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035–9.Google Scholar
American College of Obstetricians and Gynecologists. Scheduled Cesarean Delivery and the Prevention of Vertical Transmission of HIV Infection. Washington, DC: ACOG, Number 234, 2000, reaffirmed 2015. http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Scheduled-Cesarean-Delivery-and-the-Prevention-of-Vertical-Transmission-of-HIV-Infection (accessed March 2017).Google Scholar
Marcollet, A, Goffinet, F, Firtion, G, et al. Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002; 186: 784–9.Google Scholar
Madar, J, Richmond, S, Hey, E. Surfactant-deficient respiratory distress after elective delivery at “term”. Acta Paediatr 1999; 88: 1244–8.Google Scholar
Dube, MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1467–75.Google Scholar
Hitti, J, Andersen, J, McComsey, G, et al. Protease inhibitor-based therapy does not affect glucose tolerance in pregnancy: AIDS Clinical Trials Group 5084. Am J Obstet Gynecol 2007; 196: 331.e1–7.Google Scholar
Tang, JH, Sheffield, JS, Grimes, J, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006; 107: 1115–19.Google Scholar
Mandelbrot, L, Mayaux, MJ, Bongain, A, et al. Obstetric factors and mother-to-infant transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996; 175: 661–7.CrossRefGoogle Scholar
Tess, BH, Rodrigues, LC, Newell, ML, et al. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. Sao Paulo Collaborative Study for Vertical Transmission of HIV-1. AIDS 1998; 26: 513–20.Google Scholar
Gross, S, Castillo, W, Crane, M, et al. Maternal serum alpha-fetoprotein and human chorionic gonadotropin levels in women with human immunodeficiency virus. Am J Obstet Gynecol 2003; 188: 1052–6.Google Scholar
LeMeaux, JP, Tsatsaris, V, Schmitz, T, et al. Maternal biochemical serum screening for Down syndrome in pregnancy with human immunodeficiency virus infection. Obstet Gynecol 2008; 112: 223–30.Google Scholar
Brossard, P, Boulvain, M, Coll, O, et al. Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study. AIDS 2008; 22: 2013–17.Google Scholar
Peters, H, Francis, K, Harding, K, Tookey, PA, Thorne, C. Operative vaginal delivery and invasive procedures in pregnancy among women living with HIV. Eur J Obstet Gynecol Reprod Biol 2017; 210: 295–9. doi: 10.1016/j.ejogrb.2016.12.016.CrossRefGoogle ScholarPubMed
Peters, H, Byrne, L, De Ruiter, A, et al. Duration of ruptured membranes and mother-to-child HIV transmission: a prospective population-based surveillance study. BJOG 2016; 123: 975–81. doi: 10.1111/1471-0528.13442.Google Scholar
Landesman, SH, Kalish, LA, Burns, DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334: 1617–23.Google Scholar
International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15: 357–68.Google Scholar
Alvarez, JR, Bardeguez, A, Iffy, L, Apuzzio, JJ. Preterm premature rupture of membranes in pregnancies complicated by human immunodeficiency virus infection: a single center’s five-year experience. J Matern Fetal Neonatal Med 2007; 20: 853–7.Google Scholar
Gaur, AH, Dominguez, KL, Kalish, ML, et al. Practice of feeding premasticated food to infants: a potential risk factor for HIV transmission. Pediatrics 2009; 124: 658–66. doi: 10.1542/peds.2008-3614.Google Scholar
Majeed, SR, West, SK, Jiang, S, et al. Confirmation of the drug–drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy; Chicago, IL, 2017.Google Scholar
Perry, SH, Swamy, P, Preidis, GA, et al. Implementing the Jadelle implant for women living with HIV in a resource-limited setting in sub-Saharan Africa: concerns for drug interactions leading to unintended pregnancies. AIDS 2014; 28: 791–3. PubMed PMID: 24401645.Google Scholar
Scarsi, KK, Darin, KM, Nakalema, S, et al. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks. Clin Infect Dis 2016; 62: 675–82. PubMed PMID: 26646680.Google Scholar
Pyra, M, Heffron, R, Mugo, NR, et al. Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. AIDS 2015; 29: 2353–9. PubMed PMID: 26544706.CrossRefGoogle ScholarPubMed
Cohn, SE, Park, JG, Watts, DH, et al.; ACTG 5093 Protocol Team. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007; 81: 222–7.Google Scholar
Sinei, SK, Morrison, CS, Sekadde-Kigondu, C, et al. Complications of use of intrauterine devices among HIV-1–infected women. Lancet 1998; 351: 1238–41.Google Scholar
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf (accessed March 2017).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×